Join I-Mab for a KOL webinar featuring Samuel J. Klempner, MD (Associate Professor of Medicine at Massachusetts General Hospital), who will discuss new givastomig data. Givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, is being evaluated in gastric cancers. The data will be presented at the ESMO Gastrointestinal Cancers Congress (ESMO GI 2025) in a mini oral presentation on July 2, 2025.

This event will spotlight initial Phase 1b safety and efficacy results from the dose escalation study evaluating givastomig in combination with nivolumab and chemotherapy for the first line treatment of Claudin 18.2-positive gastric cancers.

I-Mab’s management team will provide an overview of the clinical development strategy for givastomig. In addition, Dr. Klempner will provide a review of the competitive landscape.

A live question and answer session will follow the formal presentations.